Table 2.
Patient | Age | Sex | Hematologic malignancy | Sample | Isolated fungal pathogen | Antifungal resistance | Previous azole exposure | Empirical antifungal treatment before identification | Treatment modification | Outcome |
---|---|---|---|---|---|---|---|---|---|---|
1 | 32 | Male | AML | Blood | Candida parapsilosis | VOR, FLC | + | CAS | – | Survived |
Blood | Candida parapsilosis | VOR, FLC | + | CAS | – | Survived | ||||
Blood | Candida glabrata | FLC | + | L-AmB | Central line removed | Survived | ||||
2 | 24 | Male | ALL | Sputum | Candida albicans | – | − | VOR | – | Survived |
3 | 51 | Male | AML | Blood | Candida parapsilosis | VOR, FLC | + | CAS | Central line removed | Survived |
Blood, wound | Candida parapsilosis | VOR, FLC | + | VOR | From VOR to AmB | Died | ||||
4 | 32 | Male | AML | Blood | Candida parapsilosis | VOR, FLC | + | CAS | – | Survived |
Blood | Candida parapsilosis | VOR, FLC | + | VOR | L-AmB | Survived | ||||
5 | 52 | Female | ALL | Blood | Geotrichum capitatum | FLC, ITR | − | CAS | Central line removed | Survived |
Blood | Geotrichum capitatum | FLC, ITR | + | VOR | – | Died | ||||
6 | 59 | Female | AML | Urine, sputum | Candida kefyr | FLC | + | L-AmB | – | Survived |
7 | 60 | Female | ALL | Blood | Candida albicans | VOR, ITR, FLC | − | CAS | – | Survived |
8 | 21 | Female | Aplastic anemia | Blood | Candida albicans | − | CAS | – | Survived | |
9 | 33 | Male | AML | Blood | Geotrichum capitatum | FLC | − | VOR | Central line removed | Survived |
10 | 60 | Female | AML | Sputum | Candida kefyr | FLC, ITR | + | VOR | – | Survived |
Sputum | Candida kefyr | FLC, ITR | + | VOR | Died | |||||
11 | 58 | Female | CLL + Burkitt’s lymphoma | Sputum | Aspergillus fumigatus | − | CAS | – | Survived | |
12 | 59 | Female | AML | BAL | Aspergillus fumigatus | − | VOR | – | Survived | |
Sputum | Aspergillus fumigatus | + | L-AmB | – | Survived | |||||
13 | 55 | Female | AML | Blood | Trichosporon asahii | AmB | + | CAS | Central line removed | Died |
14 | 63 | Female | AML | Blood | Trichosporon asahii | AmB | + | L-AmB | From AmB to VOR, central line removed | Died |
15 | 45 | Female | AML | Blood | Trichosporon asahii | AmB, ITR | − | CAS | Empirically switched to VOR | Died |
16 | 50 | Male | AML + lung cancer | Blood | Candida parapsilosis | + | VOR | From VOR to AmB, central line removed | Survived | |
Blood | Candida albicans | – | + | VOR | – | Survived | ||||
17 | 62 | Female | AML | Blood, sputum | Candida parapsilosis | + | VOR | From VOR to CAS, central line removed | Died | |
18 | 61 | Male | AML | Blood, urine | Candida albicans | + | Died | |||
19 | 73 | Female | NHL | Blood, central line | Candida albicans | + | L-AmB | Central line removed | Survived | |
20 | 35 | Male | AML | Blood | Candida albicans | + | CAS | Survived | ||
21 | 44 | Female | ALL | Blood | Candida albicans | + | L-AmB | Survived | ||
22 | 63 | Female | AML | Blood | Candida krusei | + | VOR | – | Survived | |
23 | 51 | Female | AML | Blood | Candida albicans | – | + | VOR | – | Survived |
Abbreviations: AmB, amphotericin B; ALL, acute lymphocytic leukemia; AML, acute myeloblastic leukemia; BAL, bronchoalveolar lavage; CAS, caspofungin; CLL, chronic lymphocytic leukemia; FLC, fluconazole; ITR, Itiaconazole; L-AmB, liposomal amphotericin B; NHL, non-Hodgkin lymphoma; VOR, voriconazole.